SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) – Cantor Fitzgerald decreased their FY2023 earnings per share (EPS) estimates for SELLAS Life Sciences Group in a report released on Monday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($1.04) per share for the year, down from their previous forecast of ($0.76). Cantor Fitzgerald currently has a “Overweight” rating and a $3.00 price objective on the stock. The consensus estimate for SELLAS Life Sciences Group’s current full-year earnings is ($0.86) per share. Cantor Fitzgerald also issued estimates for SELLAS Life Sciences Group’s FY2024 earnings at ($0.78) EPS.
SELLAS Life Sciences Group Price Performance
Shares of SELLAS Life Sciences Group stock opened at $0.92 on Thursday. SELLAS Life Sciences Group has a 1 year low of $0.81 and a 1 year high of $4.13. The business has a 50-day moving average of $1.25 and a two-hundred day moving average of $1.48. The company has a market capitalization of $29.52 million, a P/E ratio of -0.60 and a beta of 2.37.
Institutional Investors Weigh In On SELLAS Life Sciences Group
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
- Five stocks we like better than SELLAS Life Sciences Group
- Space Investment: How to Invest in Space Exploration
- Amazon, Target, Walmart in a race for fastest delivery
- Best Stocks Under $10.00
- Palo Alto Networks: the one security stock to rule them all
- How to Invest in Semiconductors
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.